Digital Analysis of Plasma miRNA populations in Pancreatic Cancer

胰腺癌血浆 miRNA 群的数字分析

基本信息

批准号：
9141679
负责人：
Michael L. Metzker
金额：
$ 14.99万
依托单位：
REDVAULT BIOSCIENCES, LP
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-06-07 至 2018-03-06
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9141679
关键词：
Adoption Affect Automation Biological Assay Biological Markers Biological Sciences Blood Plasma Volume Cancer Detection Cells Clinical Complex DNA Structure Data Detection Development Development Plans Devices Diagnostic Disease Management Early Diagnosis Feasibility Studies Genomics Goals Imaging technology Intervention Laboratories Lead Letters Libraries Malignant Neoplasms Malignant neoplasm of pancreas Mediating Medicine Methodology Methods MicroRNAs Molecular Monitor Nanosphere Nature Nucleic Acids Patients Pattern Phase Physiologic pulse Plasma Population Preparation Process Reporter Reproducibility Research Sampling Screening for cancer Sensitivity and Specificity Small Business Innovation Research Grant Specimen Stratification Techniques Technology Testing Time Tube Validation base cancer diagnosis circulating microRNA clinically relevant college cost cost effective density design and construction digital innovation medical schools meetings minimally invasive multiplex detection new technology novel nucleic acid detection public health relevance screening single molecule synthetic biology technology development tumor

项目摘要

DESCRIPTION (provided by applicant): The demand for robust, reliable, and minimally invasive diagnostic technologies represents a pressing need in the early detection, stratification, and surveillance of aggressive cancers. Cell-free microRNAs (miRNAs) represent a novel class of biomarkers that have shown promise during initial studies and may have significant clinical utility. The ability to efficiently and accurately identify and quantify circulating miRNA populatins is challenging however, and current approaches fail to meet the requirements of high specificity, sensitivity, accessibility, and reproducibility necessary for widespread adoption in screening and monitoring applications. In this phase I SBIR application, RedVault Biosciences proposes to establish the feasibility of a novel multiplex diagnostic platform to characterize circulating cell free miRNA populations, specifically those miRNAs of immediate utility in pancreatic cancer diagnosis, stratification, and intervention. The broadly-enabling technology leverages novel advancements in advanced molecular genomics, synthetic biology, and digital nucleic acid analysis to significantly reduce current, complex laboratory workflows and provide quantitative, reproducible and clinically informative results. Successful development of this technology could provide fundamental information to positively affect miRNA research, disease management, and patient survival.

描述（通过应用程序证明）：强大的需求和微创的诊断技术抑制了早期检测，分层的紧迫需求侵略性癌症的监视。在此阶段的筛选和监视应用中，免费的miRNA POPTIONS，特别是那些直接效用的胰腺癌，胰腺癌诊断和国际技术这项技术可能会影响miRNA研究，疾病管理和患者生存。